Praxis Precision Medicines, Inc.

NASDAQ:PRAX

Biotechnology

Healthcare
$310.90 +4.49%

+$12.13 today

Market cap
$8.69B
Beta
2.75
P/E (TTM)
-25.0
EPS (TTM)
-$11.31
52W Low $37.19High $366.52

Volume 0.63M

Average 0.45M

Returns on capital

Praxis Precision Medicines, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-34.5%

avg -111.4%

ROIC

-37.1%

avg -105.6%

ROA

-32.3%

avg -85.2%

Analysis

ROA is currently the strongest return metric at -32.3% versus its period average of -85.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Marcio Souza

President, Chief Executive Officer & DirectorUSD 2.65M470<0.01%

Timothy Edwin Kelly

Chief Financial Officer & TreasurerUSD 1.18M5331.17K0.15%

Alex Nemiroff

General Counsel & SecretaryUSD 1.03M4726.01K0.12%

Karl Hansen

Chief Technical Operations Officer————

Alyssa J. S. Wyant

Chief Regulatory & Quality Officer—51——

Megan T. Sniecinski

Chief Operating Officer—45——

Brian Spar

Chief of Staff————

Orrin Devinsky

Head of Clinical Strategy—68——

Steven Petrou

Co-Founder and President of Research & Development————

Kelly McCue

Chief People Officer————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 8, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

18

$11.08M

Net Transaction Value

−$11.08M

Net selling

Most Active

DeSimone Jill

12 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jun 24, 26

DeSimone Jill

Direct

Sell$97.7K
Jun 24, 26

DeSimone Jill

Direct

Sell$209.5K
Jun 24, 26

DeSimone Jill

Direct

Sell$382.2K
Jun 24, 26

DeSimone Jill

Direct

Sell$309.1K
Jun 24, 26

DeSimone Jill

Direct

Sell$544.1K
Jun 24, 26

DeSimone Jill

Direct

Sell$890.2K
Jun 24, 26

DeSimone Jill

Direct

Sell$314.1K
Jun 24, 26

DeSimone Jill

Direct

Sell$158.1K
Jun 24, 26

DeSimone Jill

Direct

Sell$402.8K
Jun 24, 26

DeSimone Jill

Direct

Sell$264.2K

1–10 of 18

Summary

Insiders reported 0 buys worth $0.00 and 18 sells worth $11.08M over the last 12 months. That adds up to net selling of $11.08M. DeSimone Jill was the most active insider with 12 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A7 analysts
RevenueN/AN/AN/A
N/A9 analysts
Net IncomeN/AN/AN/A
N/A9 analysts
EBITN/AN/AN/A
N/A9 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Praxis Precision Medicines, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about PRAX's management, answered from reported figures.

Who manages PRAX?

Praxis Precision Medicines, Inc. (PRAX) lists 10 active executives. The top listed executive is Karl Hansen, Chief Technical Operations Officer.

Are PRAX insiders buying or selling?

Recent insider activity shows net buying of $70.77M.